IVPK Studies in Phase II/III

April 18, 2011

Saving Cost and Time With IV Tracers and AMS

International regulators particularly from the EU, Japan and Australia are increasingly requesting absolute bioavailability data in Phase II and Phase III. Obtaining this data using the traditional cross-over clinical design can take up to a year and $1.5M to allow for IV toxicity evaluations, IV formulation development and GMP manufacture.

Xceleron’s IV tracer approach eliminates all of these hurdles by utilizing a planned Phase I study, delivering the data in just 3 additional months at a fraction of the cost of a traditional crossover approach.

Over 5 of the world’s top pharmaceutical companies have used Xceleron’s IVPK Services to generate absolute bioavailability data for their filing packages.

>> Read more: Recent Applications of AMS in Metabolism and PK
>> Contact us to discuss how we can cut costs and timelines in your Phase II and Phase III clinical trials
  • Latest News

    Xceleron is acquired by Pharmaron

    Read more »

  • What our clients are saying about us...

    "...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."

    See more client quotes »

  • Get Phase II Ready

    Find out how we can help you accelerate your drug-development program.

    Email us now »

© Xceleron 2017 All Rights Reserved.